menu

CME: Initial Treatment Steps After Any Asthma Diagnosis

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
ATS Asthma

Initial Treatment Steps After Any Asthma Diagnosis

close
0.75 credits
45 Minutes
Initial Treatment Steps After Any Asthma Diagnosis
Restart
Resume
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    Whether a patient has mild to moderate or severe asthma, there are specific actions that need to be taken to optimize control and outcomes. Effective communication between provider and patient is imperative. An evaluation for severe asthma involves confirming the diagnosis of asthma and then ruling out (and managing) possible factors that may be contributing to poor control – such as comorbid/coexisting conditions, poor adherence with recommended management strategies, and exposure to identified triggers. This is particularly important for patients with difficult-to-treat asthma, before a diagnosis of severe asthma should be considered.

  • Disclosure of Conflicts of Interest

    Method of Participation
    In order to receive credit, participants should watch the entire video. Once you have watched the video, you will continue to the online quiz and evaluation. A passing score of 80% on the quiz is required to receive credit. If you have questions about the AMA PRA Category 1 Credits™ for this CME activity, please contact Eileen Larson (elarsson@thoracic.org). There is no fee for this activity. 

    Disclosures
    Facing Severe Asthma: A Focus on New and Emerging Agents
    Dr. Wenzel has disclosed the following relevant financial relationships:
    Consultant: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Merck Sharp & Dohme Corporation, Novartis Pharmaceuticals Corporation, Sanofi Regeneron
    Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, GlaxoSmithKline, LLC., Novartis Pharmaceuticals Corporation, Sanofi Regeneron
    Speaker: AstraZeneca Pharmaceuticals LP

    Dr. Yawn has disclosed the following relevant financial relationships:
    Advisory Committee: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, LLC 

    STAFF AND REVIEWER DISCLOSURE
    Trish Brignoni, AKH, Inc., Director of Operations: has disclosed no financial relationships.
    Steve Eckert, AKH, Inc., President and CEO: has disclosed no financial relationships.
    Eileen Larsson, ATS Inc., Chief Program Officer: has disclosed no financial relationships.
    Lauren G. Lynch, ATS, Inc., Director, Education Products and Programs: has disclosed no financial relationships.
    Vickie Miller, RN, BSN, AAFP, Learning Strategist, Continuing Medical Education: has disclosed no financial relationships.
    Kim Sanders, AAFP, Manager of CME Live Activities: has disclosed no financial relationships.
    Jennifer Siegel-Gasiewski, MPA, ATS, Inc., Associate Director, Professional Accreditation: has disclosed no financial relationships.
    Lynne Kolton Schneider, PhD, Medical Writer/Interviewer: has disclosed no financial relationships.
    Michelle Turenne, ATS, Inc., Chief, Corporate Alliances & Business Development: has disclosed no financial relationships.

    DISCLOSURE DECLARATION It is the policy of ATS to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by ATS prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

    DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCT
    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    ATS DISCLAIMER
    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. ATS specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

    AAFP DISCLAIMER
    The material presented here is being made available by the American Academy of Family Physicians for methods or procedures appropriate for the medical situations discussed. Rather, it is intended to present an approach, view, statement, or opinion of the faculty, which may be helpful to others who face similar situations.

    The AAFP disclaims any and all liability for injury or other damages resulting to any individual using this material and for all claims that might arise out of the use of the techniques demonstrated therein by such individuals, whether these claims shall be asserted by a physician or any other person.

    Every effort has been made to ensure the accuracy of the data presented here. Physicians may care to check specific details such as drug doses and contraindications, etc., in standard sources prior to clinical application.

    This material might contain recommendations/guidelines developed by other organizations. Please note that although these guidelines might be included, this does not necessarily imply the endorsement by the AAFP.

    All materials herein are protected by copyright and are for the sole, personal use of the purchaser. No part of the written, oral, and broadcast production may be copied, duplicated, replicated or retransmitted without the prior permission of the applicable copyright owner.

    The unauthorized reproduction or distribution of a copyrighted work is illegal. Criminal copyright infringement, including infringement without monetary gain, is investigated by the FBI and is punishable by up to five years in federal prison and a fine of $250,000.

  • Target Audience

    This activity is designated for physicians, physician assistants and other healthcare professionals treating patients with severe asthma.

  • Learning Objectives

    Upon completion of the educational activity, participants should be able to: 

    • Outline effective communication strategies to facilitate patient’s awareness and improve the management of symptoms, trigger avoidance, treatment needs, and action plans for severe asthma.
  • Accreditation and Credit Designation Statements

    Physicians
    ACCME Credit
    The American Thoracic Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Thoracic Society designates this enduring material activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and 0 patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    AAFP Prescribed Credit
    This Enduring Material activity, Facing Severe Asthma: A Focus on Current and Emerging Agents, has been reviewed and is acceptable for credit by the American Academy of Family Physicians. Term of approval begins 11/01/2019. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Following this CME activity, participants will have the opportunity to earn an additional two Prescribed credits for participation in each Translation to Practice® exercise. Information on Translation to Practice® will be shared within the activity.

    AAFP Prescribed Credit
    Family physicians are eligible to receive AAFP Prescribed credit. At the end of each session, learners may complete the post assessment and evaluation. For family physicians to obtain a letter of participation that serves as documentation for completion of the activity, download the certificate here. AAFP Members: To get your credits added to your transcript, you will need to contact AAFP at at (800) 274-2237 or email at aafp@aafp.org.

    AMA PRA Category 1 Credit
    Physicians are eligible to receive the AMA PRA Category 1 Credits™ on completion of the online post assessment and evaluation. Physicians are responsible for reporting their own credit when applying for the AMA Physician’s Recognition Award or other certificates or credentials.

    Other Healthcare Professionals
    Healthcare professionals who are not physicians are eligible to receive CME credits on completion of the post assessment and evaluation. These individuals are responsible for reporting the CME credits to their professional organizations.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This educational activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and GlaxoSmithKline.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Whether a patient has mild to moderate or severe asthma, there are specific actions that need to be taken to optimize control and outcomes. Effective communication between provider and patient is imperative. An evaluation for severe asthma involves confirming the diagnosis of asthma and then ruling out (and managing) possible factors that may be contributing to poor control – such as comorbid/coexisting conditions, poor adherence with recommended management strategies, and exposure to identified triggers. This is particularly important for patients with difficult-to-treat asthma, before a diagnosis of severe asthma should be considered.

  • Disclosure of Conflicts of Interest

    Method of Participation
    In order to receive credit, participants should watch the entire video. Once you have watched the video, you will continue to the online quiz and evaluation. A passing score of 80% on the quiz is required to receive credit. If you have questions about the AMA PRA Category 1 Credits™ for this CME activity, please contact Eileen Larson (elarsson@thoracic.org). There is no fee for this activity. 

    Disclosures
    Facing Severe Asthma: A Focus on New and Emerging Agents
    Dr. Wenzel has disclosed the following relevant financial relationships:
    Consultant: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Merck Sharp & Dohme Corporation, Novartis Pharmaceuticals Corporation, Sanofi Regeneron
    Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, GlaxoSmithKline, LLC., Novartis Pharmaceuticals Corporation, Sanofi Regeneron
    Speaker: AstraZeneca Pharmaceuticals LP

    Dr. Yawn has disclosed the following relevant financial relationships:
    Advisory Committee: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, LLC 

    STAFF AND REVIEWER DISCLOSURE
    Trish Brignoni, AKH, Inc., Director of Operations: has disclosed no financial relationships.
    Steve Eckert, AKH, Inc., President and CEO: has disclosed no financial relationships.
    Eileen Larsson, ATS Inc., Chief Program Officer: has disclosed no financial relationships.
    Lauren G. Lynch, ATS, Inc., Director, Education Products and Programs: has disclosed no financial relationships.
    Vickie Miller, RN, BSN, AAFP, Learning Strategist, Continuing Medical Education: has disclosed no financial relationships.
    Kim Sanders, AAFP, Manager of CME Live Activities: has disclosed no financial relationships.
    Jennifer Siegel-Gasiewski, MPA, ATS, Inc., Associate Director, Professional Accreditation: has disclosed no financial relationships.
    Lynne Kolton Schneider, PhD, Medical Writer/Interviewer: has disclosed no financial relationships.
    Michelle Turenne, ATS, Inc., Chief, Corporate Alliances & Business Development: has disclosed no financial relationships.

    DISCLOSURE DECLARATION It is the policy of ATS to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by ATS prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

    DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCT
    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    ATS DISCLAIMER
    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. ATS specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

    AAFP DISCLAIMER
    The material presented here is being made available by the American Academy of Family Physicians for methods or procedures appropriate for the medical situations discussed. Rather, it is intended to present an approach, view, statement, or opinion of the faculty, which may be helpful to others who face similar situations.

    The AAFP disclaims any and all liability for injury or other damages resulting to any individual using this material and for all claims that might arise out of the use of the techniques demonstrated therein by such individuals, whether these claims shall be asserted by a physician or any other person.

    Every effort has been made to ensure the accuracy of the data presented here. Physicians may care to check specific details such as drug doses and contraindications, etc., in standard sources prior to clinical application.

    This material might contain recommendations/guidelines developed by other organizations. Please note that although these guidelines might be included, this does not necessarily imply the endorsement by the AAFP.

    All materials herein are protected by copyright and are for the sole, personal use of the purchaser. No part of the written, oral, and broadcast production may be copied, duplicated, replicated or retransmitted without the prior permission of the applicable copyright owner.

    The unauthorized reproduction or distribution of a copyrighted work is illegal. Criminal copyright infringement, including infringement without monetary gain, is investigated by the FBI and is punishable by up to five years in federal prison and a fine of $250,000.

  • Target Audience

    This activity is designated for physicians, physician assistants and other healthcare professionals treating patients with severe asthma.

  • Learning Objectives

    Upon completion of the educational activity, participants should be able to: 

    • Outline effective communication strategies to facilitate patient’s awareness and improve the management of symptoms, trigger avoidance, treatment needs, and action plans for severe asthma.
  • Accreditation and Credit Designation Statements

    Physicians
    ACCME Credit
    The American Thoracic Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Thoracic Society designates this enduring material activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and 0 patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    AAFP Prescribed Credit
    This Enduring Material activity, Facing Severe Asthma: A Focus on Current and Emerging Agents, has been reviewed and is acceptable for credit by the American Academy of Family Physicians. Term of approval begins 11/01/2019. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Following this CME activity, participants will have the opportunity to earn an additional two Prescribed credits for participation in each Translation to Practice® exercise. Information on Translation to Practice® will be shared within the activity.

    AAFP Prescribed Credit
    Family physicians are eligible to receive AAFP Prescribed credit. At the end of each session, learners may complete the post assessment and evaluation. For family physicians to obtain a letter of participation that serves as documentation for completion of the activity, download the certificate here. AAFP Members: To get your credits added to your transcript, you will need to contact AAFP at at (800) 274-2237 or email at aafp@aafp.org.

    AMA PRA Category 1 Credit
    Physicians are eligible to receive the AMA PRA Category 1 Credits™ on completion of the online post assessment and evaluation. Physicians are responsible for reporting their own credit when applying for the AMA Physician’s Recognition Award or other certificates or credentials.

    Other Healthcare Professionals
    Healthcare professionals who are not physicians are eligible to receive CME credits on completion of the post assessment and evaluation. These individuals are responsible for reporting the CME credits to their professional organizations.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This educational activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and GlaxoSmithKline.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 8/15/20